As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

Its deal with AbbVie is a collaboration and option-to-license ... principal accounting officer and treasurer. Don't miss out on Boston-area life science news. Subscribe to the Morning Edition ...

If consummated, the marriage will also give AbbVie access to Aliada's MODEL platform for delivering large-molecule drugs across the blood-brain barrier (BBB). The Boston biotech said the platform ...

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...